Product Description
Moxifloxacin is used to treat bacterial infections in many different parts of the body. It is also used to treat and prevent plague (including pneumonic and septicemic plague). Moxifloxacin belongs to the class of medicines known as quinolone antibiotics. It works by killing bacteria or preventing their growth. (Sourced from: https://www.mayoclinic.org/drugs-supplements/moxifloxacin-oral-route/side-effects/drg-20072313?p=1)
Mechanisms of Action: HERG Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, South Africa, Spain, Switzerland, Tanzania, Uganda, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: COVID-19|Capsule Opacification|Cataract|Conjunctivitis, Bacterial|Endophthalmitis|Fractures, Open|Influenza, Human|Otitis Externa|Otitis Media|Pneumonia|Pneumonia, Bacterial
Phase 2: Tuberculosis, Pulmonary
Phase 1: Healthy Volunteers|Multiple Sclerosis|Scleroderma, General
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DURATIOM | P3 |
Not yet recruiting |
Fractures, Open |
2027-12-31 |
|
| PARADIGM4TB | P2 |
Recruiting |
Tuberculosis, Pulmonary |
2027-02-24 |
|
| REMAP-CAP | P3 |
Recruiting |
Pneumonia|COVID-19|Influenza, Human |
2026-02-01 |
|
| PIND 134134 | P3 |
Not yet recruiting |
Endophthalmitis|Cataract|Capsule Opacification |
2025-10-01 |